You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
心瑋醫療-B(06609.HK)公佈中期業績 毛利率升至63.2% Captor™取栓器械商業化
格隆匯 08-30 19:35

格隆匯8月30日丨心瑋醫療-B(06609.HK)公佈中期業績,截至2021年6月30日止6個月,公司所有收益均產生自銷售ExtraFlex遠端通路導管、SupSelek微導管、Captor取栓器械及Fullblock封堵球囊導管。收益增加1,287.4%至人民幣3010萬元,主要由於ExtraFlex遠端通路導管產生的收益增加及2020年12月Captor取栓器械的商業化。

毛利由截至2020年6月30日止六個月的人民幣110萬元大幅增加至截至2021年6月30日止六個月的人民幣1910萬元。毛利率由截至2020年6月30日止六個月的50.4%上升至截至2021年6月30日止六個月的63.2%,主要是由於2020年12月商業化的Captor賺取相對較高的毛利率。

研發成本由截至2020年6月30日止六個月的人民幣1060萬元增加至截至2021年6月30日止六個月的人民幣3240萬元,主要由於公司就神經介入醫療在研器械產生的成本增加。

截至公吿日期,公司的產品組合廣泛,在中國擁有七款NMPA批准產品及16款在研產品。公司的組合從治療及預防缺血性腦卒中(涵蓋急性缺血性腦卒中及顱內動脈狹窄)擴大到出血性腦卒中的治療,包括國內首個商業化的全套支架取栓術器械,以及可能是全球首個用於顱內動脈狹窄治療的雷帕黴素顱內藥物洗脱球囊導管,該產品適用創新醫療器械特別審查程序,截至公吿日期,公司已完成患者入組。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account